drug

quemliclustat

1 story · latest Aug 5, 2026

Status: Investigational
Trials: 2 registered trials in coverage

Relationships

Developed by Arcus Biosciences, Inc.

Timeline

Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026

Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.